Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tongjiang Series Prescription for NERD with PPI Withdrawal
NCT04340297Phase 3Unknown
- Sponsor
- Xiyuan Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tongjiang granule, jianpi qinghua and Wenpi Qingwei Granules in non-erosive reflux disease (NERD) (2 arms), sponsored by Xiyuan Hospital. Primary endpoints: Visual Analogue Scale scores of reflow, heartburn and other major symptoms at 10 weeks, Discontinuation rate of acid inhibitors at 6 weeks and 1 more. Status: unknown.
02
Drugs
tongjiang granulejianpi qinghuaWenpi Qingwei Granules
03
Conditions
non-erosive reflux disease (NERD)
Beyond the preview
Go deeper on NCT04340297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340297.